… with Duchenne muscular dystrophy who are amenable to exon 51 skipping. Which study does this study hold impact? The …
… for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45 … for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45 …
… in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 … at 20 mgs/kg showed enhanced tissue exposure, greater exon skipping, and greater … in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 …
… Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 … -- AMONDYS 45 is Sarepta’s third RNA exon-skipping treatment for DMD approved in the U.S. -- -- … Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 …
… in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 … dosing SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of 10.79% and mean dystrophin expression of 6.55%, … in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 …
… Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA … Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA …
… in patients with Duchenne Muscular Dystrophy amenable to exon 51-skipping treatment. Part B of MOMENTUM will enroll males with …
… in the dystrophin gene. Most commonly, one or more exons (parts of the gene) are missing, causing errors in the … enough—or any—working dystrophin protein. The goal of exon skipping, and that of Sarepta’s proprietary technologies, is … enough—or any—working dystrophin protein. The goal of exon skipping, and that of Sarepta’s proprietary …
